Novel transcript, antisense to PSD3 (null)

The entry "novel transcript, antisense to PSD3" (ENSG00000308277) refers to a putative long non-coding RNA gene predicted to be transcribed on the opposite (antisense) strand to the PSD3 gene locus. It is not a protein-coding gene, nor is it documented as a therapeutic target such as a receptor, enzyme, transporter, or other classical drug target class. There is insufficient evidence to associate this transcript with any established biological function, disease role, or pharmacologically relevant mechanisms. Its annotation as "novel" and "antisense" indicates that it may be a computationally predicted transcript without validated function or disease association as of current knowledge. This entry appears to be included in gene databases for annotation completeness, but should not be considered a classical molecular target for drug discovery or therapeutic intervention[3]. The Ensembl gene entry ENSG00000308277 is labeled as a novel lncRNA antisense to the coding gene PSD3 (pleckstrin and Sec7 domain containing 3), which is a well-characterized protein-coding gene with known aliases, domains, and biological functions[1][7]. However, the antisense/transcript entry itself is non-coding and lacks the molecular features, disease links, or pharmacological relevance typically required of drug targets. As such, this entry is likely not appropriate for drug development or therapeutic targeting in its own right, and its primary relevance may be as a subject for basic research into non-coding RNA biology—if validated. This is not a conventional therapeutic target; the entry is a non-coding RNA, lacks function, is not druggable, and is included mostly for annotation. Furthermore, as a number-labeled, "novel transcript, antisense to PSD3" entry, it is likely of marginal relevance for structured drug target databases and should be flagged as incorrect for those applications[3].

Other names

Novel transcript, antisense to PSD3ENSG00000308277